Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials

BackgroundPhase III trials of the malaria vaccine, RTS, S, are now underway across multiple sites of varying transmission intensity in Africa. Heterogeneity in exposure, vaccine response and waning of efficacy may bias estimates of vaccine efficacy.MethodsTheoretical arguments are used to identify the expected effects of a) heterogeneity in exposure to infectious bites; b) heterogeneity in individual's response to the vaccine; and c) waning efficacy on measures of vaccine efficacy from clinical trials for an infection-blocking vaccine.ResultsHeterogeneity in exposure and vaccine response leads to a smaller proportion of trial participants becoming infected than one would expect in a homogeneous setting. This causes estimates of vaccine efficacy from clinical trials to be underestimated if transmission heterogeneity is ignored, and overestimated if heterogeneity in vaccine response is ignored. Waning of vaccine efficacy can bias estimates of vaccine efficacy in both directions.ConclusionsFailure to account for heterogeneities in exposure and response, and waning of efficacy in clinical trials can lead to biased estimates of malaria vaccine efficacy. Appropriate methods to reduce these biases need to be used to ensure accurate interpretation and comparability between trial sites of results from the upcoming Phase III clinical trials of RTS, S.

[1]  C. Dye,et al.  Heterogeneities in the transmission of infectious agents: implications for the design of control programs. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Dye,et al.  Population dynamics of mosquito-borne disease: effects of flies which bite some people more frequently than others. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[3]  A. Prentice,et al.  Impact of nutritional status on antibody responses to different vaccines in undernourished Gambian children , 2003, Acta paediatrica.

[4]  Inácio Mandomando,et al.  Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. , 2009, The Journal of infectious diseases.

[5]  J. Trape,et al.  Vector density gradients and the epidemiology of urban malaria in Dakar, Senegal. , 1992, The American journal of tropical medicine and hygiene.

[6]  M. Elizabeth Halloran,et al.  A Frailty Mixture Model for Estimating Vaccine Efficacy , 1996 .

[7]  C. Farrington,et al.  Estimation of Waning Vaccine Efficacy , 2002 .

[8]  M. Demoitié,et al.  Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. , 2008, The New England journal of medicine.

[9]  M E Halloran,et al.  Interpretation and estimation of vaccine efficacy under heterogeneity. , 1992, American journal of epidemiology.

[10]  M. Tanner,et al.  Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. , 2008, The New England journal of medicine.

[11]  P. Carnevale,et al.  Etude de l'agressivité d' Anopheles gambiae A en fonction de l'âge et du sexe des appâts humains , 1978 .

[12]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[13]  R. Snow,et al.  Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya , 2008, The Lancet.

[14]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[15]  M. Kolczak,et al.  Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. , 2003, The American journal of tropical medicine and hygiene.

[16]  Thomas A. Smith,et al.  Modeling a field trial of the RTS,S/AS02A malaria vaccine. , 2006, The American journal of tropical medicine and hygiene.

[17]  Peter G. Smith,et al.  MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives. , 2009, Vaccine.

[18]  K. Marsh,et al.  Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure , 2009, Infection and Immunity.

[19]  W. Takken,et al.  Odor-mediated behavior of Afrotropical malaria mosquitoes. , 1999, Annual Review of Entomology.

[20]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[21]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[22]  R. Snow,et al.  The trouble with eaves; house entry by vectors of malaria. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[23]  K. Marsh,et al.  What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity , 2009, Malaria Journal.

[24]  M E Halloran,et al.  Estimability and interpretation of vaccine efficacy using frailty mixing models. , 1996, American journal of epidemiology.

[25]  I. Kleinschmidt,et al.  Marked increase in child survival after four years of intensive malaria control. , 2009, The American journal of tropical medicine and hygiene.

[26]  P G Smith,et al.  Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. , 1984, International journal of epidemiology.

[27]  T. Lang,et al.  Malaria vaccine trial endpoints – bridging the gaps between trial design, public health and the next generation of vaccines , 2009, Parasite immunology.

[28]  W. Takken,et al.  Differential attractiveness of isolated humans to mosquitoes in Tanzania. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[29]  Nicolas Maire,et al.  What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines , 2008, PloS one.

[30]  Q. Bassat,et al.  Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children , 2009, PloS one.

[31]  D. Conway,et al.  Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis , 2008, The Lancet.

[32]  J. Dushoff,et al.  The entomological inoculation rate and Plasmodium falciparum infection in African children , 2005, Nature.

[33]  A. Prentice,et al.  Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan , 2006, Tropical medicine & international health : TM & IH.

[34]  D. Wypij,et al.  Estimation of vaccine efficacy in a repeated measures study under heterogeneity of exposure or susceptibility to infection , 2008, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.